Drug firm Lupin on Tuesday said inspection of a unit of its Mandideep facility in Madhya Pradesh by the French National Agency for Medicines and Health Products Safety (ANSM) has been completed with no major observations.
The good manufacturing practices (GMP) inspection of company's finished product manufacturing facility (Unit-1) at Mandideep by the ANSM has been completed, Lupin said in a statement.
The inspection was conducted between April 8 to April 12, 2019, it added.
"The ANSM inspection closed with no critical or major observations," Lupin said.
Shares of Lupin Ltd were trading at Rs 755.65 per scrip on BSE, down 0.11 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app